Companies
/Healthcare
CapsoVision, Inc. Common Stock
$6.54
▲ $0.04 (+0.62%) today
Markets closed · 12:08am ET
CV at a Glance
Valuation
- Market cap
- $345.9M
Profitability
- Revenue (TTM)
- $13.9M
- Profit margin
- -214.7%
- EPS (TTM)
- $-0.45
Price
- 52-week range
- $4 – $15
- Street target
- $9.50
Earnings
- Next report
- Nov 12, 2026
Headquartered in Saratoga, CA Fiscal year ends December NASDAQ: CV capsovision.com
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions for the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The company has served over 176,000 patients with CapsoCam Plus. Its product pipeline includes CapsoCam Colon with enhanced AI for non-invasive colon imaging and polyp detection, AI Highlights for AI-assisted physician review of capsule endoscopy studies, and CapsoCam UGI for pancreatic cancer detection. The company's proprietary platform is designed to expand across multiple GI indications, including esophageal and pancreatic disorders. CapsoVision trades on NASDAQ under the ticker CV. Updated
Frequently Asked Questions
What does CapsoVision do?
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions for the detection and screening of gastrointestinal diseases.
What is the CV stock price target?
The Wall Street consensus 12-month price target for CV is $9.50.